Eravacycline Dihydrochloride and Tafinlar

• Generic Name: eravacycline
• Dosage Forms: n.a.
• Other Brand Names: Xerava

Eravacycline dihydrochloride is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of eravacycline dihydrochloride and other antibacterial drugs, eravacycline dihydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Eravacycline dihydrochloride is not indicated for the treatment of complicated urinary tract infections (cUTI).

• Generic Name: dabrafenib
• Dosage Forms: capsule
• Other Brand Names: Tafinlar

Tafinlar (dabrafenib) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Tafinlar is used alone or in combination with another medicine called trametinib (Mekinist) to treat certain types of cancer in people who have a "BRAF" gene mutation.

Tafinlar is for use in treating:

• melanoma (skin cancer) that cannot be treated with surgery or has spread to other parts of the body, or to prevent melanoma from coming back after surgery;

• non-small cell lung cancer that has spread to other parts of the body; or

• advanced or metastatic thyroid cancer that has spread and for which there are no other treatment options.